Ogkologos | Ogkologos.com | Page 75

Home Authors Posts by Ogkologos

4396 POSTS 0 COMMENTS

ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular...

Ogkologos - August 7, 2024

More Immunotherapy Options Approved for Treating Endometrial Cancer

Ogkologos - August 6, 2024

FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor...

Ogkologos - August 6, 2024

Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type...

Ogkologos - August 5, 2024

Screening People at High Risk for Pancreatic Cancer May Help Them...

Ogkologos - August 2, 2024

EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with...

Ogkologos - August 2, 2024

FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular...

Ogkologos - July 31, 2024

Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in...

Ogkologos - July 30, 2024

AI-Based Score as a Selection Tool for Supplemental MRI After Negative...

Ogkologos - July 29, 2024

Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone...

Ogkologos - July 29, 2024

1...747576...440 Page 75 of 440

MOST POPULAR

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

October 15, 2021

6 Things That Helped Me Think Positively During Cancer: A Patient...

August 16, 2022

No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as...

April 14, 2023

A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most...

May 15, 2020

HOT NEWS

Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than...

Time to take on 9 new Cancer Grand Challenges

Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses

EMA Recommends Extending Indications for Lisocabtagene Maraleucel